Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819597 | 0.88 | L3MBTL1 (0.42) | L3MBTL1MEN1KMT2ASQORCNR1 | |
| SCHEMBL30475444 | 0.87 | GRM5 (0.39) | ARL3MBTL1SQORCNR1FEN1 | |
| SCHEMBL25029383 | 0.87 | GRM5 (0.39) | ARL3MBTL1SQORCNR1FEN1 | |
| SCHEMBL26044686 | 0.85 | MEN1 (0.48) | L3MBTL1MEN1KMT2ASQORCNR1 | |
| SCHEMBL25031014 | 0.83 | AR (0.42) | ARL3MBTL1MEN1KMT2ASQOR | |
| SCHEMBL29013156 | 0.81 | FEN1 (0.45) | ARFEN1 | |
| SCHEMBL25935014 | 0.81 | GABRG2 (0.49) | L3MBTL1MEN1KMT2ASQORCNR1 | |
| SCHEMBL25952894 | 0.81 | AR (0.43) | ARL3MBTL1MEN1KMT2ASQOR | |
| SCHEMBL25482306 | 0.81 | DYRK1A (0.44) | L3MBTL1SQORDYRK1ADYRK2DYRK1B | |
| SCHEMBL31645625 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | AR 3336/4885L3MBTL1 964/4885MEN1 3403/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | AR 3336/4885L3MBTL1 964/4885MEN1 3403/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | AR 3720/4885L3MBTL1 2040/4885MEN1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.